🧫

Behavioral assessment of APP/PSEN1/GD3S triple-mutant mice

active
experiment Created: 2026-04-10T22:32:02 By: etl-v1-backfill Quality: 50% ✓ SciDEX ID: exp-8611f56b-0e18-40e2-a0d4-0be2bff633ec
🧫 Experiment Protocol ValidationAlzheimer's diseaseSt8sia1APP/PSEN1/GD3S-/- triple-transgenic miceproposed
Triple-transgenic mice (APP/PSEN1/GD3S-/-) were generated by crossing APP/PSEN1 Alzheimer's disease model mice with GD3S knockout mice. These triple-mutant mice, along with control groups including wild-type, GD3S-/-, and APP/PSEN1 double-transgenic mice, were subjected to a battery of reference-memory tasks to assess cognitive function. The behavioral testing aimed to determine whether elimination of GD3S could rescue the memory impairments typically observed in APP/PSEN1 mice. The experiment demonstrated that while APP/PSEN1 mice showed robust memory deficits, the triple-mutant mice performed at normal levels comparable to wild-type and GD3S-/- controls.
PRIMARY OUTCOME
reference-memory task performance
EXPECTED OUTCOMES
1. The intervention targeting St8sia1 shifts reference-memory task performance in the predicted direction relative to the matched control arm. 2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects. 3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
- Prespecified primary endpoint (reference-memory task performance) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study. - The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset. - Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish APP/PSEN1/GD3S-/- triple-transgenic mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for St8sia1, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure reference-memory task performance together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: Triple-transgenic mice (APP/PSEN1/GD3S-/-) were generated by crossing APP/PSEN1 Alzheimer's disease model mice with GD3S knockout mice. These triple-mutant mice, along with control groups including wild-type, GD3S-/-, and APP/PSEN1 double-transgenic mice, were
🧫 Experiment Extras
PATHWAY
amyloid processing and ganglioside biosynthesis pathways
MARKET PRICE
$0.50
STATUS
proposed
Metadataorigin_type: v1_polymorphic_backfill
origin_typev1_polymorphic_backfill
source_tableexperiments
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.